Silas Inman· @SilasInman · X·· 2026-04-21Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
Zoldonrasib Displays Early Safety, Efficacy in Pretreated KRAS G12D–Mutated NSCLC
https://
onclive.com/view/zoldonras
ib-displays-early-safety-efficacy-in-pretreated-kras-g12d-mutated-nsclc
… #aacr26
Heat 0 · 0 likes · 0 replies · 0 reposts
Source: Silas Inman · x.com